Physician

Dheeraj Kodali, M.D.

According to 2025 Medicare claims, Dheeraj Kodali, M.D. (NPI: 1508179607) practices hematology/oncology in the Modesto, CA market, with the plurality of this provider's patient population coming from Stanislaus, CA. This provider's primary affiliated billing organization is STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (NPI: 1922175074; TIN: 20-3850829) and primary practice location at 95350-5581. Kodali is affiliated with the Main Street Rural Health Sycamore ACO LLC (ACO ID: A5403), participating under the MSSP model.

Kodali's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 331 traditional Medicare patients, billed 96,135 HCPCS/CPT codes, and received $1,393,266 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,601 prescription claims across 253 beneficiaries totaling $4,390,649 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 60 claims. Open Payments data shows 83 records totaling $40,364. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $12,316 to $1,393,266. Similarly, Part D prescription costs have moved sharply higher in recent years, from $230,531 to $4,390,649. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	57	128	$12,316
2019	138	550	$39,906
2020	246	1,000	$67,481
2021	239	5,735	$88,790
2022	204	49,016	$997,327
2023	282	59,342	$743,425
2024	331	96,135	$1,393,266

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	125	1,508	$230,531
2016	85	245	$17,949
2017	50	186	$18,500
2018	22	60	$68,521
2019	50	315	$310,646
2020	89	746	$494,630
2021	122	691	$877,636
2022	137	840	$1,266,739
2023	182	1,341	$3,716,572
2024	253	1,601	$4,390,649

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	22	$1,039
2022	N/R	15	$717
2023	N/R	24	$4,190
2024	N/R	60	$1,587

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	45	45	$169
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	50	54	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	532	$96
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	41	90	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	69	86	$68

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	50	1,390	$672,280
Jakafi	Ruxolitinib Phosphate	26	780	$464,890
Revlimid	Lenalidomide	28	784	$426,509
Pomalyst	Pomalidomide	13	358	$230,627
Calquence	Acalabrutinib Maleate	14	420	$215,436

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$1,010
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	22	$276

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$1,809	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$38,555	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dheeraj Kodali, M.D.?

Tedicare shows public-source Medicare data for Dheeraj Kodali, M.D. (NPI 1508179607), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dheeraj Kodali, M.D. have ACO affiliation data?

Dheeraj Kodali, M.D. is shown with ACO affiliation data for Main Street Rural Health Sycamore ACO LLC (MSSP, ACO ID A5403).

What billing organization is linked to Dheeraj Kodali, M.D.?

Dheeraj Kodali, M.D. is linked to STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (billing NPI 1922175074) in the available physician profile data.

Does Dheeraj Kodali, M.D. have Open Payments data?

Dheeraj Kodali, M.D. has 83 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.